![]() |
Trials |
A randomized, douple-blind, phase 2/3 study of relatlimab combined with nivolumab versus nivolumab in participants with previously untreated metastatic or unresectable melanomaCancer type: Melanoma Phase: II Principal Investigator: Hernberg Micaela Country: FI Keywords: Finland, Helsinki Status: Open for inclusion Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03470922 |